Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Based on Circulating Tumor DNA-minimal Residual Disease Technology : A Prospective, Observational Study

NCT05969938 is registered in ClinicalTrials.gov with WeiWei Xiao as lead sponsor.

NCT NCT05969938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Based on Circulating Tumor DNA-minimal Residual Disease Technology : A Prospective, Observational Study
Lead sponsor
WeiWei Xiao
Phase
Observational
Overall status
Unknown status
Start date
June 21, 2023
Completion date
August 31, 2024
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor dna, minimal residual disease, neoadjuvant chemoradiotherapy, rectal adenocarcinoma